# EDGAR Filing Document

**Accession Number:** 0000896435
**File Stem:** 0000896435-26-000361
**Filing Date:** 2026-5
**Character Count:** 50318
**Document Hash:** 6510bbc0e2c7d28f994eb30d669bbd19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896435-26-000361.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0000896435-26-000361

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**PERIOD START**: 20261231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIM VARIABLE INSURANCE FUNDS (INVESCO VARIABLE INSURANCE FUNDS)
- **CENTRAL INDEX KEY:** 0000896435

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-07452
- **FILM NUMBER:** 261028516

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046
- **BUSINESS PHONE:** 7136261919

**MAIL ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIM VARIABLE INSURANCE FUNDS
- **DATE OF NAME CHANGE:** 20000719

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIM VARIABLE INSURANCE FUNDS INC
- **DATE OF NAME CHANGE:** 19930714

## Series and Classes Contracts Data

### INVESCO V.I. Health Care Fund (Series ID: S000000193)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000000432 | Series I     |  |
| C000000433 | Series II    |  |

## Nport-Ex

**Schedule of Investments**<sup>(a)</sup> 

*March 31, 2026*

*(Unaudited)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Common Stocks & Other Equity Interests–96.04%** | **Common Stocks & Other Equity Interests–96.04%** | **Common Stocks & Other Equity Interests–96.04%** |
| **Biotechnology–28.88%** | **Biotechnology–28.88%** | **Biotechnology–28.88%** |
| AbbVie, Inc. | 25391 | &nbsp;&nbsp; $5522289 |
| Alnylam Pharmaceuticals, Inc.<sup>(b)</sup>  | 1741 | &nbsp;&nbsp; 576045 |
| argenx SE, ADR (Netherlands)<sup>(b)</sup>  | 6892 | &nbsp;&nbsp; 5032883 |
| Arrowhead Pharmaceuticals, Inc.<sup>(b)</sup>  | 7737 | &nbsp;&nbsp; 485110 |
| Ascendis Pharma A/S, ADR (Denmark)<sup>(b)</sup>  | 7074 | &nbsp;&nbsp; 1618036 |
| BeOne Medicines Ltd., ADR<sup>(b)</sup>  | 1685 | &nbsp;&nbsp; 500395 |
| BridgeBio Pharma, Inc.<sup>(b)</sup>  | 28134 | &nbsp;&nbsp; 2089231 |
| Caris Life Sciences, Inc.<sup>(b)</sup>  | 14375 | &nbsp;&nbsp; 257025 |
| Cogent Biosciences, Inc.<sup>(b)</sup>  | 9662 | &nbsp;&nbsp; 371890 |
| Cytokinetics, Inc.<sup>(b)</sup>  | 6260 | &nbsp;&nbsp; 412597 |
| Dianthus Therapeutics, Inc.<sup>(b)</sup>  | 4361 | &nbsp;&nbsp; 365975 |
| Gilead Sciences, Inc. | 43847 | &nbsp;&nbsp; 6110956 |
| Halozyme Therapeutics, Inc.<sup>(b)</sup>  | 20180 | &nbsp;&nbsp; 1304233 |
| Insmed, Inc.<sup>(b)</sup>  | 15670 | &nbsp;&nbsp; 2562358 |
| Ionis Pharmaceuticals, Inc.<sup>(b)</sup>  | 13962 | &nbsp;&nbsp; 1048407 |
| Madrigal Pharmaceuticals, Inc.<sup>(b)(c)</sup>  | 2753 | &nbsp;&nbsp; 1441113 |
| Mirum Pharmaceuticals, Inc.<sup>(b)</sup>  | 2424 | &nbsp;&nbsp; 223929 |
| Natera, Inc.<sup>(b)</sup>  | 11191 | &nbsp;&nbsp; 2238088 |
| Nuvalent, Inc., Class A<sup>(b)</sup>  | 4325 | &nbsp;&nbsp; 443096 |
| Palvella Therapeutics, Inc.<sup>(b)</sup>  | 2691 | &nbsp;&nbsp; 335433 |
| Protagonist Therapeutics, Inc.<sup>(b)(c)</sup>  | 13525 | &nbsp;&nbsp; 1425535 |
| Regeneron Pharmaceuticals, Inc. | 3228 | &nbsp;&nbsp; 2494082 |
| Revolution Medicines, Inc.<sup>(b)</sup>  | 4495 | &nbsp;&nbsp; 437139 |
| Rhythm Pharmaceuticals, Inc.<sup>(b)</sup>  | 3992 | &nbsp;&nbsp; 347184 |
| Twist Bioscience Corp.<sup>(b)(c)</sup>  | 9702 | &nbsp;&nbsp; 461039 |
| United Therapeutics Corp.<sup>(b)(c)</sup>  | 2998 | &nbsp;&nbsp; 1777754 |
| Vertex Pharmaceuticals, Inc.<sup>(b)</sup>  | 6623 | &nbsp;&nbsp; 2957434 |
|  |  | &nbsp;&nbsp; 42839256 |
| **Health Care Distributors–8.94%** | **Health Care Distributors–8.94%** | **Health Care Distributors–8.94%** |
| Cardinal Health, Inc. | 11823 | &nbsp;&nbsp; 2498318 |
| Cencora, Inc. | 17242 | &nbsp;&nbsp; 5416402 |
| McKesson Corp. | 6187 | &nbsp;&nbsp; 5353982 |
|  |  | &nbsp;&nbsp; 13268702 |
| **Health Care Equipment–7.55%** | **Health Care Equipment–7.55%** | **Health Care Equipment–7.55%** |
| Boston Scientific Corp.<sup>(b)</sup>  | 26142 | &nbsp;&nbsp; 1640411 |
| Edwards Lifesciences Corp.<sup>(b)</sup>  | 20667 | &nbsp;&nbsp; 1655013 |
| Globus Medical, Inc., Class A<sup>(b)</sup>  | 11395 | &nbsp;&nbsp; 981793 |
| IDEXX Laboratories, Inc.<sup>(b)</sup>  | 3792 | &nbsp;&nbsp; 2130687 |
| Intuitive Surgical, Inc.<sup>(b)</sup>  | 3973 | &nbsp;&nbsp; 1831513 |
| IRhythm Holdings, Inc.<sup>(b)</sup>  | 4175 | &nbsp;&nbsp; 492734 |
| LeMaitre Vascular, Inc. | 5730 | &nbsp;&nbsp; 625544 |
| STERIS PLC | 4309 | &nbsp;&nbsp; 952849 |
| Stryker Corp. | 1391 | &nbsp;&nbsp; 457069 |
| TransMedics Group, Inc.<sup>(b)(c)</sup>  | 4371 | &nbsp;&nbsp; 434521 |
|  |  | &nbsp;&nbsp; 11202134 |
| **Health Care Facilities–4.05%** | **Health Care Facilities–4.05%** | **Health Care Facilities–4.05%** |
| Encompass Health Corp. | 14073 | &nbsp;&nbsp; 1361281 |
| HCA Healthcare, Inc. | 6432 | &nbsp;&nbsp; 3043880 |
| Tenet Healthcare Corp.<sup>(b)</sup>  | 8514 | &nbsp;&nbsp; 1606677 |
|  |  | &nbsp;&nbsp; 6011838 |

---

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Health Care REITs–2.09%** | **Health Care REITs–2.09%** | **Health Care REITs–2.09%** |
| Welltower, Inc. | 15671 | &nbsp;&nbsp; $3098314 |
| **Health Care Services–6.24%** | **Health Care Services–6.24%** | **Health Care Services–6.24%** |
| BillionToOne, Inc.<sup>(b)(c)</sup>  | 1921 | &nbsp;&nbsp; 151644 |
| BrightSpring Health Services, Inc.<sup>(b)</sup>  | 62746 | &nbsp;&nbsp; 2673607 |
| CVS Health Corp. | 19815 | &nbsp;&nbsp; 1423113 |
| GeneDx Holdings Corp.<sup>(b)(c)</sup>  | 6601 | &nbsp;&nbsp; 423916 |
| Guardant Health, Inc.<sup>(b)</sup>  | 24692 | &nbsp;&nbsp; 2280800 |
| Labcorp Holdings, Inc. | 3544 | &nbsp;&nbsp; 945575 |
| Quest Diagnostics, Inc. | 4671 | &nbsp;&nbsp; 915423 |
| RadNet, Inc.<sup>(b)</sup>  | 7870 | &nbsp;&nbsp; 439854 |
|  |  | &nbsp;&nbsp; 9253932 |
| **Health Care Supplies–0.89%** | **Health Care Supplies–0.89%** | **Health Care Supplies–0.89%** |
| Medline, Inc., Class A<sup>(b)</sup>  | 29508 | &nbsp;&nbsp; 1313106 |
| **Health Care Technology–0.26%** | **Health Care Technology–0.26%** | **Health Care Technology–0.26%** |
| Heartflow, Inc.<sup>(b)(c)</sup>  | 15766 | &nbsp;&nbsp; 383587 |
| **Life Sciences Tools & Services–4.98%** | **Life Sciences Tools & Services–4.98%** | **Life Sciences Tools & Services–4.98%** |
| BioLife Solutions, Inc.<sup>(b)</sup>  | 19732 | &nbsp;&nbsp; 376486 |
| Bio-Techne Corp. | 5823 | &nbsp;&nbsp; 304310 |
| &nbsp;&nbsp;&nbsp; Charles River Laboratories International, <br> Inc.<sup>(b)</sup>  | 964 | &nbsp;&nbsp; 166290 |
| Lonza Group AG (Switzerland) | 1915 | &nbsp;&nbsp; 1228508 |
| Medpace Holdings, Inc.<sup>(b)</sup>  | 1616 | &nbsp;&nbsp; 775987 |
| Mettler-Toledo International, Inc.<sup>(b)</sup>  | 1363 | &nbsp;&nbsp; 1719016 |
| Repligen Corp.<sup>(b)</sup>  | 4183 | &nbsp;&nbsp; 492841 |
| Thermo Fisher Scientific, Inc. | 4714 | &nbsp;&nbsp; 2317072 |
|  |  | &nbsp;&nbsp; 7380510 |
| **Managed Health Care–2.09%** | **Managed Health Care–2.09%** | **Managed Health Care–2.09%** |
| Alignment Healthcare, Inc.<sup>(b)</sup>  | 40222 | &nbsp;&nbsp; 708712 |
| HealthEquity, Inc.<sup>(b)</sup>  | 3741 | &nbsp;&nbsp; 312635 |
| UnitedHealth Group, Inc. | 7708 | &nbsp;&nbsp; 2085708 |
|  |  | &nbsp;&nbsp; 3107055 |
| **Pharmaceuticals–30.07%** | **Pharmaceuticals–30.07%** | **Pharmaceuticals–30.07%** |
| AstraZeneca PLC (United Kingdom) | 32828 | &nbsp;&nbsp; 6474338 |
| Axsome Therapeutics, Inc.<sup>(b)</sup>  | 11411 | &nbsp;&nbsp; 1928687 |
| Eli Lilly and Co. | 14751 | &nbsp;&nbsp; 13567527 |
| Galderma Group AG, Class A (Switzerland) | 6470 | &nbsp;&nbsp; 1271573 |
| Johnson & Johnson | 35303 | &nbsp;&nbsp; 8629465 |
| Ligand Pharmaceuticals, Inc.<sup>(b)</sup>  | 5939 | &nbsp;&nbsp; 1185721 |
| Merck & Co., Inc. | 27966 | &nbsp;&nbsp; 3364030 |
| Phathom Pharmaceuticals, Inc.<sup>(b)</sup>  | 24059 | &nbsp;&nbsp; 267296 |
| Rapport Therapeutics, Inc.<sup>(b)</sup>  | 14308 | &nbsp;&nbsp; 447697 |
| Royalty Pharma PLC, Class A | 57339 | &nbsp;&nbsp; 2750552 |
| Sandoz Group AG (Switzerland) | 22014 | &nbsp;&nbsp; 1724817 |
| Tarsus Pharmaceuticals, Inc.<sup>(b)</sup>  | 10074 | &nbsp;&nbsp; 706691 |
| UCB S.A. (Belgium) | 7580 | &nbsp;&nbsp; 2283830 |
|  |  | &nbsp;&nbsp; 44602224 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Common Stocks & Other Equity Interests <br> (Cost $95,503,214) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Common Stocks & Other Equity Interests <br> (Cost $95,503,214) | &nbsp;&nbsp; 142460658 |

---

See accompanying notes which are an integral part of this schedule.

**Invesco V.I. Health Care Fund**

------

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares** | **Shares** | **Value** |
| **Money Market Funds–3.78%** | **Money Market Funds–3.78%** | **Money Market Funds–3.78%** | **Money Market Funds–3.78%** |
| &nbsp;&nbsp;&nbsp; Invesco Government & Agency Portfolio, <br> Institutional Class, 3.58%<sup>(d)(e)</sup>  | &nbsp;&nbsp;&nbsp; Invesco Government & Agency Portfolio, <br> Institutional Class, 3.58%<sup>(d)(e)</sup>  | 1919183 | &nbsp;&nbsp; $1919183 |
| &nbsp;&nbsp;&nbsp; Invesco Treasury Portfolio, Institutional Class, <br> 3.56%<sup>(d)(e)</sup>  | &nbsp;&nbsp;&nbsp; Invesco Treasury Portfolio, Institutional Class, <br> 3.56%<sup>(d)(e)</sup>  | 3680431 | &nbsp;&nbsp; 3680431 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $5,599,614) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $5,599,614) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $5,599,614) | &nbsp;&nbsp; 5599614 |
| &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES <br> (excluding investments purchased with <br> cash collateral from securities on <br> loan)-99.82% (Cost $101,102,828)<br>|  |  | &nbsp;&nbsp; 148060272 |
| **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** |
| **Money Market Funds–4.00%** | **Money Market Funds–4.00%** | **Money Market Funds–4.00%** | **Money Market Funds–4.00%** |
| &nbsp;&nbsp;&nbsp; Invesco Private Government Fund, <br> 3.63%<sup>(d)(e)(f)</sup>  | &nbsp;&nbsp;&nbsp; Invesco Private Government Fund, <br> 3.63%<sup>(d)(e)(f)</sup>  | 1653340 | &nbsp;&nbsp; 1653340 |

---

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Money Market Funds–(continued)** | **Money Market Funds–(continued)** | **Money Market Funds–(continued)** |
| Invesco Private Prime Fund, 3.80%<sup>(d)(e)(f)</sup>  | 4282136 | &nbsp;&nbsp; $4282564 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Investments Purchased with Cash Collateral <br> from Securities on Loan (Cost $5,935,904) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Investments Purchased with Cash Collateral <br> from Securities on Loan (Cost $5,935,904) | &nbsp;&nbsp; 5935904 |
| &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES–103.82% <br> (Cost $107,038,732) | &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES–103.82% <br> (Cost $107,038,732) | &nbsp;&nbsp; 153996176 |
| OTHER ASSETS LESS LIABILITIES—(3.82)% | OTHER ASSETS LESS LIABILITIES—(3.82)% | &nbsp;&nbsp; (5661921)<br>|
| NET ASSETS–100.00% | NET ASSETS–100.00% | &nbsp;&nbsp; $148334255 |

---

Investment Abbreviations:

ADR – American Depositary Receipt <br> REIT – Real Estate Investment Trust

Notes to Schedule of Investments:

<sup>(a)</sup> Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's. 

<sup>(b)</sup> Non-income producing security.

<sup>(c)</sup> All or a portion of this security was out on loan at March 31, 2026.

<sup>(d)</sup> Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended March 31, 2026. 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Value** <br>**December 31, 2025**<br>| **Purchases** <br>**at Cost**<br>| **Proceeds** <br>**from Sales**<br>| **Change in** <br>**Unrealized** <br>**Appreciation**<br>| **Realized** <br>**Gain** <br>**(Loss)**<br>| **Value** <br>**March 31, 2026**<br>| **Dividend Income** |
| **Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Invesco Government & Agency Portfolio, Institutional <br> Class<br>| $1395079 | &nbsp;&nbsp; $5243655 | &nbsp;&nbsp; $(4719551) | &nbsp;&nbsp; $- | &nbsp;&nbsp; $- | &nbsp;&nbsp; $1919183 | &nbsp;&nbsp; $16516 |
| Invesco Treasury Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp; 2707097 | &nbsp;&nbsp;&nbsp; 9738217 | &nbsp;&nbsp;&nbsp; (8764883) | &nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp; 3680431 | &nbsp;&nbsp;&nbsp; 31451 |
| **Investments Purchased with Cash Collateral from** <br> **Securities on Loan:**<br>|  |  |  |  |  |  |  |
| Invesco Private Government Fund | &nbsp;&nbsp;&nbsp; 1993793 | &nbsp;&nbsp; 17746254 | &nbsp;&nbsp; (18086707) | &nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp; 1653340 | &nbsp;&nbsp; 16,017\* |
| Invesco Private Prime Fund | &nbsp;&nbsp;&nbsp; 5183957 | &nbsp;&nbsp; 21123836 | &nbsp;&nbsp; (22023735) | &nbsp;&nbsp; - | &nbsp;&nbsp; (1494) | &nbsp;&nbsp;&nbsp; 4282564 | &nbsp;&nbsp; 39,579\* |
| Total | $11279926 | &nbsp;&nbsp; $53851962 | &nbsp;&nbsp; $(53594876) | &nbsp;&nbsp; $- | &nbsp;&nbsp; $(1494) | &nbsp;&nbsp; $11535518 | &nbsp;&nbsp; $103563 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(e)</sup> The rate shown is the 7-day SEC standardized yield as of March 31, 2026. <br> <sup>(f)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.

See accompanying notes which are an integral part of this schedule.

**Invesco V.I. Health Care Fund**

------

**Notes to Quarterly Schedule of Portfolio Holdings**

*March 31, 2026*

*(Unaudited)*

**NOTE 1—Additional Valuation Information**

Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment's assigned level:

Level 1 – Prices are determined using quoted prices in an active market for identical assets.

Level 2 – Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others. When market movements occur after the close of the relevant foreign securities markets, foreign securities may be fair valued utilizing an independent pricing service.

Level 3 – Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Advisers, Inc.'s assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of March 31, 2026. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| <br>**Investments in Securities** |  |  |  |  |
| Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;&nbsp; $135951930 | &nbsp;&nbsp;&nbsp;&nbsp; $6508728 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $142460658 |
| Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp; 5599614 | &nbsp;&nbsp;&nbsp;&nbsp; 5935904 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 11535518 |
| **Total Investments** | &nbsp;&nbsp;&nbsp;&nbsp; $141551544 | &nbsp;&nbsp;&nbsp;&nbsp; $12444632 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $153996176 |

---

**Invesco V.I. Health Care Fund**

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** AIM Variable Insurance Funds (Invesco Variable Insurance Funds)

- **b. Investment Company Act file number:** 811-07452

- **c. CIK number of Registrant:** 0000896435

- **d. LEI of Registrant:** FC4UULIMJMGKBDUARB13

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 11 Greenway Plaza

  - **City:** Houston

  - **State:** TX

  - **Foreign country:** US

  - **Zip / Postal Code:** 77046-1173

  - **Telephone number:** 800-959-4246

**Item A.2. Information about the Series.**

- **a. Name of Series:** Invesco V.I. Health Care Fund

- **b. EDGAR series identifier (if any):** S000000193

- **c. LEI of Series:** 549300PW4U695XQU6377

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-12-31

- **b. Date as of which information is reported:** 2026-03-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $154497360.17

**Total Liabilities:** $6073616.81

**Net Assets:** $148423743.36

**Cash Not Reported:** $0.97

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000000433 | -0.96%               | 0.82%                | -6.12%               |
| Class ID C000000432 | -0.90%               | 0.84%                | -6.09%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $2705207.98              | $-4189723.07                               |
| Month 2  | $3246421.23              | $-2005015.60                               |
| Month 3  | $1387656.16              | $-11083679.16                              |

### Schedule of Portfolio Investments

| Name                                           | Title                                                      | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Insmed Inc.                                    | Insmed Inc.                                                | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     15670 | NS      | $2562358.40   | 1.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                                 | Lonza Group AG                                             | CUSIP: H50524133<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |      1915 | NS      | $1228507.64   | 0.83%             |  |  |  | No            |                  2 | On Loan: No      |
| Galderma Group AG                              | Galderma Group AG, Class A                                 | CUSIP: H3301B107<br>LEI: 89450001OK6O8ELQ4584 | Long             | EC               | CORP              | CH        |      6470 | NS      | $1271572.90   | 0.86%             |  |  |  | No            |                  2 | On Loan: No      |
| Charles River Laboratories International, Inc. | Charles River Laboratories International, Inc.             | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |       964 | NS      | $166290.00    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Ligand Pharmaceuticals Inc.                    | Ligand Pharmaceuticals Inc.                                | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |      5939 | NS      | $1185721.35   | 0.80%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp.                               | CVS Health Corp.                                           | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |     19815 | NS      | $1423113.30   | 0.96%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                                | AstraZeneca PLC                                            | CUSIP: G0593M107<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     32828 | NS      | $6474338.16   | 4.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Mirum Pharmaceuticals, Inc.                    | Mirum Pharmaceuticals, Inc.                                | CUSIP: 604749101<br>LEI: 254900YZKR40F7F27K81 | Long             | EC               | CORP              | US        |      2424 | NS      | $223929.12    | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics, Inc.                      | Axsome Therapeutics, Inc.                                  | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     11411 | NS      | $1928687.22   | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly and Co.                              | Eli Lilly and Co.                                          | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |     14751 | NS      | $13567527.27  | 9.14%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc.                  | Thermo Fisher Scientific Inc.                              | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |      4714 | NS      | $2317072.42   | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Treasury Portfolio                     | Invesco Treasury Portfolio, Institutional Class            | CUSIP: 825252406<br>LEI: 5493004B3TM8ZIDDDC39 | Long             | STIV             | RF                | US        |   3680431 | NS      | $3680431.35   | 2.48%             |  |  |  | No            |                  1 | On Loan: No      |
| HCA Healthcare, Inc.                           | HCA Healthcare, Inc.                                       | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |      6432 | NS      | $3043879.68   | 2.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc.                    | Vertex Pharmaceuticals Inc.                                | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |      6623 | NS      | $2957434.42   | 1.99%             |  |  |  | No            |                  1 | On Loan: No      |
| TransMedics Group, Inc.                        | TransMedics Group, Inc.                                    | CUSIP: 89377M109<br>LEI: 549300060GVOSMWARH50 | Long             | EC               | CORP              | US        |      4371 | NS      | $434521.11    | 0.29%             |  |  |  | No            |                  1 | On Loan: —       |
| Phathom Pharmaceuticals, Inc.                  | Phathom Pharmaceuticals, Inc.                              | CUSIP: 71722W107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     24059 | NS      | $267295.49    | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent, Inc.                                 | Nuvalent, Inc., Class A                                    | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      4325 | NS      | $443096.25    | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora, Inc.                                  | Cencora, Inc.                                              | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |     17242 | NS      | $5416401.88   | 3.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals, Inc.                | Regeneron Pharmaceuticals, Inc.                            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      3228 | NS      | $2494081.92   | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences, Inc.                          | Gilead Sciences, Inc.                                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |     43847 | NS      | $6110956.39   | 4.12%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc.                        | UnitedHealth Group Inc.                                    | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |      7708 | NS      | $2085707.72   | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Globus Medical, Inc.                           | Globus Medical, Inc., Class A                              | CUSIP: 379577208<br>LEI: 5299003M2P4CIK0RF205 | Long             | EC               | CORP              | US        |     11395 | NS      | $981793.20    | 0.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC                             | Royalty Pharma PLC, Class A                                | CUSIP: G7709Q104<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |     57339 | NS      | $2750551.83   | 1.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp.                        | Boston Scientific Corp.                                    | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |     26142 | NS      | $1640410.50   | 1.11%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc.                                    | AbbVie Inc.                                                | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |     25391 | NS      | $5522288.59   | 3.72%             |  |  |  | No            |                  1 | On Loan: No      |
| United Therapeutics Corp.                      | United Therapeutics Corp.                                  | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |      2998 | NS      | $1777754.04   | 1.20%             |  |  |  | No            |                  1 | On Loan: —       |
| Palvella Therapeutics, Inc.                    | Palvella Therapeutics, Inc.                                | CUSIP: 697947109<br>LEI: 254900AJDH8PAOOI5T33 | Long             | EC               | CORP              | US        |      2691 | NS      | $335433.15    | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics, Inc.                    | Halozyme Therapeutics, Inc.                                | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |     20180 | NS      | $1304233.40   | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| U C B S.A.                                     | U C B S.A.                                                 | CUSIP: B93562120<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |      7580 | NS      | $2283829.71   | 1.54%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical, Inc.                       | Intuitive Surgical, Inc.                                   | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |      3973 | NS      | $1831513.27   | 1.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera, Inc.                                   | Natera, Inc.                                               | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     11191 | NS      | $2238088.09   | 1.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Rapport Therapeutics, Inc.                     | Rapport Therapeutics, Inc.                                 | CUSIP: 75383L102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14308 | NS      | $447697.32    | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Sandoz Group AG                                | Sandoz Group AG                                            | CUSIP: H7140B103<br>LEI: 5493000JWK6XWFEUD320 | Long             | EC               | CORP              | CH        |     22014 | NS      | $1724816.40   | 1.16%             |  |  |  | No            |                  2 | On Loan: No      |
| Medline Inc.                                   | Medline Inc., Class A                                      | CUSIP: 58507V107<br>LEI: 984500FAN6J1P8566D43 | Long             | EC               | CORP              | US        |     29508 | NS      | $1313106.00   | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp.                               | Bio-Techne Corp.                                           | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |      5823 | NS      | $304309.98    | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| RadNet, Inc.                                   | RadNet, Inc.                                               | CUSIP: 750491102<br>LEI: 529900RECG94V2IZJ970 | Long             | EC               | CORP              | US        |      7870 | NS      | $439854.30    | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| IRhythm Holdings, Inc.                         | IRhythm Holdings, Inc.                                     | CUSIP: 450056106<br>LEI: 549300FJI72RJGDQS384 | Long             | EC               | CORP              | US        |      4175 | NS      | $492733.50    | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Labcorp Holdings Inc.                          | Labcorp Holdings Inc.                                      | CUSIP: 504922105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      3544 | NS      | $945574.64    | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                            | Ascendis Pharma A/S, ADR                                   | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      7074 | NS      | $1618036.02   | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| BioLife Solutions, Inc.                        | BioLife Solutions, Inc.                                    | CUSIP: 09062W204<br>LEI: 549300G2IVCMC2TJDW72 | Long             | EC               | CORP              | US        |     19732 | NS      | $376486.56    | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp.                                  | Stryker Corp.                                              | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |      2121 | NS      | $696939.39    | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co., Inc.                              | Merck & Co., Inc.                                          | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     27966 | NS      | $3364030.14   | 2.27%             |  |  |  | No            |                  1 | On Loan: No      |
| HealthEquity, Inc.                             | HealthEquity, Inc.                                         | CUSIP: 42226A107<br>LEI: 529900LRJU1RAFQHM467 | Long             | EC               | CORP              | US        |      3741 | NS      | $312635.37    | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines, Inc.                     | Revolution Medicines, Inc.                                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |      4495 | NS      | $437138.75    | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| GeneDx Holdings Corp.                          | GeneDx Holdings Corp.                                      | CUSIP: 81663L200<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      6601 | NS      | $423916.22    | 0.29%             |  |  |  | No            |                  1 | On Loan: —       |
| Invesco Private Prime Fund                     | Invesco Private Prime Fund                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |   4282136 | NS      | $4282564.21   | 2.89%             |  |  |  | No            |                  2 | On Loan: No      |
| McKesson Corp.                                 | McKesson Corp.                                             | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |      6187 | NS      | $5353982.32   | 3.61%             |  |  |  | No            |                  1 | On Loan: No      |
| BillionToOne, Inc.                             | BillionToOne, Inc.                                         | CUSIP: 090168105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1921 | NS      | $151643.74    | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| BridgeBio Pharma, Inc.                         | BridgeBio Pharma, Inc.                                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     28134 | NS      | $2089230.84   | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals, Inc.                    | Ionis Pharmaceuticals, Inc.                                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     13962 | NS      | $1048406.58   | 0.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Cardinal Health, Inc.                          | Cardinal Health, Inc.                                      | CUSIP: 14149Y108<br>LEI: CCU46N3GJMF4OK4N7U60 | Long             | EC               | CORP              | US        |     11823 | NS      | $2498318.13   | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd.                           | BeOne Medicines Ltd., ADR                                  | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |      1685 | NS      | $500394.45    | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Tenet Healthcare Corp.                         | Tenet Healthcare Corp.                                     | CUSIP: 88033G407<br>LEI: 0W9AIBT6U6ADJ2I8HK17 | Long             | EC               | CORP              | US        |      8514 | NS      | $1606676.94   | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health, Inc.                          | Guardant Health, Inc.                                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |     24692 | NS      | $2280800.04   | 1.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics, Inc.                    | Dianthus Therapeutics, Inc.                                | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |      4361 | NS      | $365975.12    | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Quest Diagnostics Inc.                         | Quest Diagnostics Inc.                                     | CUSIP: 74834L100<br>LEI: 8MCWUBXQ0WE04KMXBX50 | Long             | EC               | CORP              | US        |      4671 | NS      | $915422.58    | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Twist Bioscience Corp.                         | Twist Bioscience Corp.                                     | CUSIP: 90184D100<br>LEI: 549300T23BL59LCOH584 | Long             | EC               | CORP              | US        |      9702 | NS      | $461039.04    | 0.31%             |  |  |  | No            |                  1 | On Loan: —       |
| Caris Life Sciences, Inc.                      | Caris Life Sciences, Inc.                                  | CUSIP: 142152107<br>LEI: 549300LX5LO78M5VPY43 | Long             | EC               | CORP              | US        |     14375 | NS      | $257025.00    | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| LeMaitre Vascular, Inc.                        | LeMaitre Vascular, Inc.                                    | CUSIP: 525558201<br>LEI: 549300FZUBUB7MHY8R17 | Long             | EC               | CORP              | US        |      5730 | NS      | $625544.10    | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals, Inc.                   | Rhythm Pharmaceuticals, Inc.                               | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |      3992 | NS      | $347184.24    | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics, Inc.                             | Cytokinetics, Inc.                                         | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |      6260 | NS      | $412596.60    | 0.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Arrowhead Pharmaceuticals, Inc.                | Arrowhead Pharmaceuticals, Inc.                            | CUSIP: 04280A100<br>LEI: 549300O3CSB8T7OZ3D66 | Long             | EC               | CORP              | US        |      7737 | NS      | $485109.90    | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Government & Agency Portfolio          | Invesco Government & Agency Portfolio, Institutional Class | CUSIP: 825252885<br>LEI: 5493007T1J7WZ5QI1A47 | Long             | STIV             | RF                | US        |   1919183 | NS      | $1919182.63   | 1.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Welltower Inc.                                 | Welltower Inc.                                             | CUSIP: 95040Q104<br>LEI: 254900F33BIAR82QTA19 | Long             | EC               | CORP              | US        |     15671 | NS      | $3098313.41   | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp.                     | Edwards Lifesciences Corp.                                 | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |     20667 | NS      | $1655013.36   | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Mettler-Toledo International Inc.              | Mettler-Toledo International Inc.                          | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |      1363 | NS      | $1719015.60   | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                              | Johnson & Johnson                                          | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |     35303 | NS      | $8629465.32   | 5.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Medpace Holdings, Inc.                         | Medpace Holdings, Inc.                                     | CUSIP: 58506Q109<br>LEI: 549300H8TYEUVTW14A54 | Long             | EC               | CORP              | US        |      1616 | NS      | $775987.04    | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Encompass Health Corp.                         | Encompass Health Corp.                                     | CUSIP: 29261A100<br>LEI: 549300FVRPM9DRQZRG64 | Long             | EC               | CORP              | US        |     15280 | NS      | $1478034.40   | 1.00%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories, Inc.                       | IDEXX Laboratories, Inc.                                   | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |      3792 | NS      | $2130686.88   | 1.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Private Government Fund                | Invesco Private Government Fund                            | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |   1653340 | NS      | $1653339.80   | 1.11%             |  |  |  | No            |                  2 | On Loan: No      |
| Cogent Biosciences, Inc.                       | Cogent Biosciences, Inc.                                   | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      9662 | NS      | $371890.38    | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Tarsus Pharmaceuticals, Inc.                   | Tarsus Pharmaceuticals, Inc.                               | CUSIP: 87650L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     10074 | NS      | $706691.10    | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Alignment Healthcare, Inc.                     | Alignment Healthcare, Inc.                                 | CUSIP: 01625V104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     40222 | NS      | $708711.64    | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Steris PLC                                     | Steris PLC                                                 | CUSIP: G8473T100<br>LEI: 549300F1857N5E6G6T48 | Long             | EC               | CORP              | IE        |      4309 | NS      | $952849.17    | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics, Inc.                 | Protagonist Therapeutics, Inc.                             | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     13525 | NS      | $1425535.00   | 0.96%             |  |  |  | No            |                  1 | On Loan: —       |
| BrightSpring Health Services, Inc.             | BrightSpring Health Services, Inc.                         | CUSIP: 10950A106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     62746 | NS      | $2673607.06   | 1.80%             |  |  |  | No            |                  1 | On Loan: No      |
| argenx SE                                      | argenx SE, ADR                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |      6892 | NS      | $5032883.00   | 3.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp.                                 | Repligen Corp.                                             | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |      4183 | NS      | $492841.06    | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Heartflow, Inc.                                | Heartflow, Inc.                                            | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     15766 | NS      | $383586.78    | 0.26%             |  |  |  | No            |                  1 | On Loan: —       |
| Alnylam Pharmaceuticals, Inc.                  | Alnylam Pharmaceuticals, Inc.                              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      1741 | NS      | $576044.67    | 0.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals, Inc.                 | Madrigal Pharmaceuticals, Inc.                             | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |      2753 | NS      | $1441112.91   | 0.97%             |  |  |  | No            |                  1 | On Loan: —       |

### Signature

**Date Signed:** 2026-04-30

**Name of Applicant:** AIM Variable Insurance Funds (Invesco Variable Insurance Funds)

**Signature:** Adrien Deberghes

**Name of Signer:** Adrien Deberghes

**Title:** Principal Financial Officer and Treasurer